GlaukosGKOS -3.09%79 5-Year ROIIC % is 395.35 as of Dec. 2025. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review. Among 734 Medical Devices & Instruments companies, Glaukos ranks better than 96.73% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Glaukos's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 395.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Glaukos's 5-Year ROIIC % or its related term are showing as below:
GKOS's 5-Year ROIIC % is ranked better than 96.73% of 734
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs GKOS: 395.35
Glaukos (NYSE:GKOS) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Glaukos 5-Year ROIIC % Related Terms
Glaukos 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Glaukos's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs BIO, BRKR, PODD: 5-Year ROIIC % Comparison
For the Medical Devices subindustry, Glaukos's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Glaukos's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Glaukos (GKOS) has a 5-Year ROIIC % of 395.35 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Glaukos and its competitors. According to the industry distribution chart, Glaukos ranks #24 out of 734 companies in the Medical Devices & Instruments industry, placing it in the top 3.3%.
Is Glaukos' 5-Year ROIIC % too high?
Glaukos' current 5-Year ROIIC % is 395.35. The Medical Devices & Instruments industry median 5-Year ROIIC % is 0.95. Glaukos' value of 395.35 is 41515.8% above this industry median. Based on the distribution chart, Glaukos ranks #24 out of 734 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Glaukos has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' 5-Year ROIIC % compare to BIO and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #24 out of 734 companies for 5-Year ROIIC %. This places Glaukos in the top 3% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 0.95. Glaukos' value of 395.35 is 41515.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.95, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current 5-Year ROIIC % of 395.35 is 41515.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current 5-Year ROIIC % is 395.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $137.80 — trading 1.7% above its estimated fair value. The current 5-Year ROIIC % is 395.35 and 41515.8% above the Medical Devices & Instruments industry median of 0.95. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Glaukos (GKOS), the current 5-Year ROIIC % is 395.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $137.80 is trading 1.7% above its estimated GF Value™ of $135.47.
GuruFocus considers Glaukos to be Fairly Valued.
Key valuation signals for GKOS:
5-Year ROIIC %: 395.35
GF Value™: $135.47 vs. price of $137.80 (1.7% above fair value)
Industry Position: 41515.8% above the Medical Devices & Instruments median (#24 of 734)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score
Get the complete analysis for GKOS
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
